This paper summarizes the theoretical basis of aromatherapy in traditional Chinese medicine （TCM） for treating depression， from the perspectives of aromatic properties in relieving constraint and dispersing stagnation， awakening the spleen and promoting its transportation function， harmonizing the five zang （脏） organs， and regulating emotions to nurture mental well-being. The potential clinical applications of TCM aromatherapy are also discussed. In the future， it is necessary to strengthen high-quality clinical evidence about aromatherapy， deepen mechanism studies with an emphasis on the "nose-brain" pathway， explore aromatherapy-based integrative mind-body intervention strategies， assess and control potential safety risks， as well as promote the translation of clinical findings and the development of novel dosage forms. These efforts will help standardize and advance the clinical application of TCM aromatherapy in the management of depression.

This paper summarizes the theoretical basis of aromatherapy in traditional Chinese medicine （TCM） for treating depression， from the perspectives of aromatic properties in relieving constraint and dispersing stagnation， awakening the spleen and promoting its transportation function， harmonizing the five zang （脏） organs， and regulating emotions to nurture mental well-being. The potential clinical applications of TCM aromatherapy are also discussed. In the future， it is necessary to strengthen high-quality clinical evidence about aromatherapy， deepen mechanism studies with an emphasis on the "nose-brain" pathway， explore aromatherapy-based integrative mind-body intervention strategies， assess and control potential safety risks， as well as promote the translation of clinical findings and the development of novel dosage forms. These efforts will help standardize and advance the clinical application of TCM aromatherapy in the management of depression.

Purpose To predict the 2015 American thyroid association(ATA)recurrence risk stratification based on ultrasonographic features and Hashimoto's thyroiditis(HT)-specific antibody status of papillary thyroid carcinoma(PTC)in the context of HT.Materials and Methods A retrospective analysis was conducted on the ultrasonographic and clinical data of 479 patients with coexisting PTC and HT,who underwent their first thyroid surgery at the First Medical Center of Chinese PLA General Hospital from January 2017 to December 2019.All patients were divided in chronological order into a training group(n=327)and a validation group(n=152).Multivariate Logistic regression analysis was utilized to identify independent factors associated with high recurrence risk stratification according to the ATA guidelines.Predictive models were constructed and screened,and the efficacy of these models was evaluated using the area under the curve,calibration curves and Brier scores.Results Multivariate Logistic regression analysis identified the following as independent predictive factors for high recurrence risk stratification:multifocal malignancy of nodules(OR=3.812,95％CI 1.275-11.397,P=0.017),nodule contact with the capsule(OR=8.012,95％CI 1.647-38.972,P=0.010),microcalcifications(OR=4.220,95％CI 1.302-13.678,P=0.016),an aspect ratio＞1(OR=4.017,95％CI 1.286-12.548,P=0.017),abundant nodule vascularity(OR=6.120,95％CI 2.225-16.832,P＜0.001),maximum nodule diameter ≥1 cm(OR=4.784,95％CI 1.360-16.833,P=0.015),a glandular echo characteristic of typical HT(OR=0.114,95％CI 0.039-0.330,P＜0.001),and anti-thyroid peroxidase antibody monopositivity(OR=0.088,95％CI 0.006-1.299,P=0.077).The predictive model demonstrated strong performance,as evidenced by the area under the curve of 0.942(95％CI 0.911-0.972)in the training set and 0.933(95％CI 0.878-0.990)in the validation set.Both groups exhibited well-fitting calibration curves.The Brier scores were 0.054 and 0.058 for the training and validation sets,respectively,indicating excellent predictive efficacy of the model.Conclusion The preoperative prediction model,based on ultrasonographic features combined with antibody status,demonstrates good efficacy in assessing ATA recurrence risk stratification for coexisting PTC and HT patients,which can assist clinicians in formulating treatment plans.

Objective To investigate the toxicity attenuation and efficacy potentiation effects of Shiquan Dabu Tang (SDT) on high dose chemotherapy in T739 mice with bladder carcinoma. Methods Mouse bladder carcinoma tissue was inoculated subcutaneously into T739 mice to establish tumor-beating mice model. The tumor-bearing mice were randomly divided into a CTX group (100, 200, 400 mg/Kg respectively), a SDT group (high or low dose respectively), a high-dose SDT combined with 200 mg/Kg CTX group and a control group. The body weight, diameter of tumor nodules and complete blood count were observed subsequently. Results Different doses of SDT could effectively inhibit tumor growth in mice. SDT + CTX treatment significantly prolonged the survival time of mice by 49.4±23.3 days (P<0.01, 0.05, 0.01), compared with high dose SDT treatment (17.4±5.77) days, 200 mg/kg CTX treatment (23±14.02) days and control group (11.75±2.06) days respectively. The peripheral platelet count increased more significantly in mice treated with SDT within a week as compared to mice without SDT treatment (P<0.05). The peripheral RBC count and liB concentration increased more significantly in mice treated with SDT for 2 weeks as compared to mice without SDT treatment (P<0.05). Conclusions SDT could enhance the anti-tumor effects of high dose CTX on tumor-bearing mice and reduce toxicity in its peripheral red blood cells. The results showed that SDT combined with high dose of CTX chemotherapy had toxicity attenuation and efficacy potentiation effects in tumor-beating T739 mice.